The American Society of Hematology’s (ASH) annual meeting is a well-established indicator of the innovations that are coming down the pipeline for hematologic diseases. CBPartners’ Cell and Gene Therapy Center of Excellence explored eight promising presentations from the CAR T event.
Principal, Value, Access, and Pricing
Ms. Pikus leads engagement work within the Value, Access and Pricing Practice and drives the Cell and Gene Therapy Centre of Excellence at CBPartners. In this capacity, Ms. Pikus has supported a range of qualitative and quantitative engagements to inform current and future portfolio strategy. Her geographical expertise includes the US and EU, where she routinely advises on strategic pricing and market access decisions for both existing and pipeline products.
In the pursuit of client support, Ms. Pikus has conducted assessments across a range of therapeutic areas, including oncology, hemophilia, respiratory and behavioral health spaces, as well as exploratory research in the biosimilars space. Her work within oncology spans product-specific and portfolio-based strategy, aimed at providing stakeholder-tailored insights to enhance product value and access. Ms. Pikus serves as one of the firm’s experts on USA market dynamics, as well as within the cell and gene therapy space, monitoring the current and evolving impact of these novel technologies to the global healthcare landscape.
Ms. Pikus holds an MSc and BS in Bioengineering from the University of Pennsylvania.
Connect with Julia Pikus
August 22, 2019 | Blogs
In 2017, the first therapy designed to genetically modify patients’ own T-cells to attack cancer was FDA-approved, but are CAR T-cell therapies close to meeting the remaining needs of patients? CBPartners' Cell and Gene Therapy Center of Excellence investigates the current challenges and limitations of this therapy.